bortezomib injection 1 MG and 2.5 MG VIAL Adverse Reactions

(bortezomib for injection)

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are also discussed in other sections of the labeling:

Peripheral Neuropathy [see Warnings and Precautions (5.1)]
Hypotension [see Warnings and Precautions (5.2)]
Cardiac Toxicity [see Warnings and Precautions (5.3)]
Pulmonary Toxicity [see Warnings and Precautions (5.4)]
Posterior Reversible Encephalopathy Syndrome (PRES) [see Warnings and Precautions (5.5)]
Gastrointestinal Toxicity [see Warnings and Precautions (5.6)]
Thrombocytopenia/Neutropenia [see Warnings and Precautions (5.7)]
Tumor Lysis Syndrome [see Warnings and Precautions (5.8)]
Hepatic Toxicity [see Warnings and Precautions (5.9)]
Thrombotic Microangiopathy [see Warnings and Precautions (5.10)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Summary of Clinical Trial in Patients with Previously Untreated Multiple Myeloma

Table 9 describes safety data from 340 patients with previously untreated multiple myeloma who received bortezomib (1.3 mg/m2) administered intravenously in combination with melphalan (9 mg/m2) and prednisone (60 mg/m2) in a prospective randomized study.

The safety profile of bortezomib in combination with melphalan/prednisone is consistent with the known safety profiles of both bortezomib and melphalan/prednisone.

Table 9: Most Commonly Reported Adverse Reactions (≥10% in the Bortezomib, Melphalan and Prednisone Arm) with Grades 3 and ≥4 Intensity in the Previously Untreated Multiple Myeloma Study
Bortezomib, Melphalan and Prednisone
(n = 340)
Melphalan and Prednisone
(n = 337)
Body SystemTotalToxicity Grade, n (%)TotalToxicity Grade, n (%)
Adverse Reactionn (%)3≥4n (%)3≥4
*
Represents High Level Term Peripheral Neuropathies NEC

Blood and Lymphatic System Disorders

  Thrombocytopenia

164 (48)

60 (18)

57 (17)

140 (42)

48 (14)

39 (12)

  Neutropenia

160 (47)

101 (30)

33 (10)

143 (42)

77 (23)

42 (12)

  Anemia

109 (32)

41 (12)

4 (1)

156 (46)

61 (18)

18 (5)

  Leukopenia

108 (32)

64 (19)

8 (2)

93 (28)

53 (16)

11 (3)

  Lymphopenia

78 (23)

46 (14)

17 (5)

51 (15)

26 (8)

7 (2)

Gastrointestinal Disorders

  Nausea

134 (39)

10 (3)

0

70 (21)

1 (<1)

0

  Diarrhea

119 (35)

19 (6)

2 (1)

20 (6)

1 (<1)

0

  Vomiting

87 (26)

13 (4)

0

41 (12)

2 (1)

0

  Constipation

77 (23)

2 (1)

0

14 (4)

0

0

  Abdominal pain upper

34 (10)

1 (<1)

0

20 (6)

0

0

Nervous System Disorders

  Peripheral neuropathy*

156 (46)

42 (12)

2 (1)

4 (1)

0

0

  Neuralgia

117 (34)

27 (8)

2 (1)

1 (<1)

0

0

  Paresthesia

42 (12)

6 (2)

0

4 (1)

0

0

General Disorders and Administration Site Conditions

  Fatigue

85 (25)

19 (6)

2 (1)

48 (14)

4 (1)

0

  Asthenia

54 (16)

18 (5)

0

23 (7)

3 (1)

0

  Pyrexia

53 (16)

4 (1)

0

19 (6)

1 (<1)

1 (<1)

Infections and Infestations

  Herpes Zoster

39 (11)

11 (3)

0

9 (3)

4 (1)

0

Metabolism and Nutrition Disorders

  Anorexia

64 (19)

6 (2)

0

19 (6)

0

0

Skin and Subcutaneous Tissue Disorders

  Rash

38 (11)

2 (1)

0

7 (2)

0

0

Psychiatric Disorders

  Insomnia

35 (10)

1 (<1)

0

21 (6)

0

0

Relapsed Multiple Myeloma Randomized Study of Bortezomib vs Dexamethasone

The safety data described below and in Table 10 reflect exposure to either bortezomib (n=331) or dexamethasone (n=332) in a study of patients with relapsed multiple myeloma. Bortezomib was administered intravenously at doses of 1.3 mg/m2 twice weekly for two out of three weeks (21 day cycle). After eight 21 day cycles patients continued therapy for three 35 day cycles on a weekly schedule. Duration of treatment was up to 11 cycles (nine months) with a median duration of six cycles (4.1 months). For inclusion in the trial, patients must have had measurable disease and one to three prior therapies. There was no upper age limit for entry. Creatinine clearance could be as low as 20 mL/min and bilirubin levels as high as 1.5 times the upper limit of normal. The overall frequency of adverse reactions was similar in men and women, and in patients <65 and ≥65 years of age. Most patients were Caucasian [see Clinical Studies (14.1)].

Among the 331 bortezomib-treated patients, the most commonly reported (>20%) adverse reactions overall were nausea (52%), diarrhea (52%), fatigue (39%), peripheral neuropathies (35%), thrombocytopenia (33%), constipation (30%), vomiting (29%), and anorexia (21%). The most commonly reported (>20%) adverse reaction reported among the 332 patients in the dexamethasone group was fatigue (25%). Eight percent (8%) of patients in the bortezomib-treated arm experienced a Grade 4 adverse reaction; the most common reactions were thrombocytopenia (4%) and neutropenia (2%). Nine percent (9%) of dexamethasone-treated patients experienced a Grade 4 adverse reaction. All individual dexamethasone-related Grade 4 adverse reactions were less than 1%.

Serious Adverse Reactions and Adverse Reactions Leading to Treatment Discontinuation in the Relapsed Multiple Myeloma Study of Bortezomib vs Dexamethasone

Serious adverse reactions are defined as any reaction that results in death, is life-threatening, requires hospitalization or prolongs a current hospitalization, results in a significant disability, or is deemed to be an important medical event. A total of 80 (24%) patients from the bortezomib treatment arm experienced a serious adverse reaction during the study, as did 83 (25%) dexamethasone-treated patients. The most commonly reported serious adverse reactions in the bortezomib treatment arm were diarrhea (3%), dehydration, herpes zoster, pyrexia, nausea, vomiting, dyspnea, and thrombocytopenia (2% each). In the dexamethasone treatment group, the most commonly reported serious adverse reactions were pneumonia (4%), hyperglycemia (3%), pyrexia, and psychotic disorder (2% each).

A total of 145 patients, including 84 (25%) of 331 patients in the bortezomib treatment group and 61 (18%) of 332 patients in the dexamethasone treatment group were discontinued from treatment due to adverse reactions. Among the 331 bortezomib-treated patients, the most commonly reported adverse reaction leading to discontinuation was peripheral neuropathy (8%). Among the 332 patients in the dexamethasone group, the most commonly reported adverse reactions leading to treatment discontinuation were psychotic disorder and hyperglycemia (2% each).

Four deaths were considered to be bortezomib-related in this relapsed multiple myeloma study: one case each of cardiogenic shock, respiratory insufficiency, congestive heart failure and cardiac arrest. Four deaths were considered dexamethasone-related: two cases of sepsis, one case of bacterial meningitis, and one case of sudden death at home.

Most Commonly Reported Adverse Reactions in the Relapsed Multiple Myeloma Study of Bortezomib vs Dexamethasone

The most common adverse reactions from the relapsed multiple myeloma study are shown in Table 10. All adverse reactions with incidence ≥10% in the bortezomib arm are included.

Table 10: Most Commonly Reported Adverse Reactions (≥10% in Bortezomib Arm), with Grades 3 and 4 Intensity in the Relapsed Multiple Myeloma Study of Bortezomib vs Dexamethasone (N=663)
Bortezomib
(N = 331)
Dexamethasone
(N = 332)
Adverse ReactionsAllGrade 3Grade 4AllGrade 3Grade 4
*
Represents High Level Term Peripheral Neuropathies NEC

Any Adverse Reactions

324 (98)

193 (58)

28 (8)

297 (89)

110 (33)

29 (9)

Nausea

172 (52)

8 (2)

0

31 (9)

0

0

Diarrhea NOS

171 (52)

22 (7)

0

36 (11)

2 (<1)

0

Fatigue

130 (39)

15 (5)

0

82 (25)

8 (2)

0

Peripheral neuropathies*

115 (35)

23 (7)

2 (<1)

14 (4)

0

1 (< 1)

Thrombocytopenia

109 (33)

80 (24)

12 (4)

11 (3)

5 (2)

1 (< 1)

Constipation

99 (30)

6 (2)

0

27 (8)

1 (<1)

0

Vomiting NOS

96 (29)

8 (2)

0

10 (3)

1 (<1)

0

Anorexia

68 (21)

8 (2)

0

8 (2)

1 (<1)

0

Pyrexia

66 (20)

2 (<1)

0

21 (6)

3 (<1)

1 (< 1)

Paresthesia

64 (19)

5 (2)

0

24 (7)

0

0

Anemia NOS

63 (19)

20 (6)

1 (<1)

21 (6)

8 (2)

0

Headache NOS

62 (19)

3 (<1)

0

23 (7)

1 (<1)

0

Neutropenia

58 (18)

37 (11)

8 (2)

1 (<1)

1 (<1)

0

Rash NOS

43 (13)

3 (<1)

0

7 (2)

0

0

Appetite decreased NOS

36 (11)

0

0

12 (4)

0

0

Dyspnea NOS

35 (11)

11 (3)

1 (<1)

37 (11)

7 (2)

1 (< 1)

Abdominal pain NOS

35 (11)

5 (2)

0

7 (2)

0

0

Weakness

34 (10)

10 (3)

0

28 (8)

8 (2)

0

Safety Experience from the Phase 2 Open-Label Extension Study in Relapsed Multiple Myeloma

In the Phase 2 extension study of 63 patients, no new cumulative or new long-term toxicities were observed with prolonged bortezomib treatment. These patients were treated for a total of 5.3 to 23 months, including time on bortezomib in the prior bortezomib study [see Clinical Studies (14.1)].

Safety Experience from the Phase 3 Open-Label Study of Bortezomib Subcutaneous vs Intravenous in Relapsed Multiple Myeloma

The safety and efficacy of bortezomib administered subcutaneously were evaluated in one Phase 3 study at the recommended dose of 1.3 mg/m2. This was a randomized, comparative study of bortezomib subcutaneous vs intravenous in 222 patients with relapsed multiple myeloma. The safety data described below and in Table 11 reflect exposure to either bortezomib subcutaneous (N=147) or bortezomib intravenous (N=74) [see Clinical Studies (14.1)].

Table 11: Most Commonly Reported Adverse Reactions (≥10%), with Grade 3 and ≥4 Intensity in the Relapsed Multiple Myeloma Study (N=221) of Bortezomib Subcutaneous vs Intravenous
Subcutaneous
(N = 147)
Intravenous
(N = 74)
Body SystemTotalToxicity Grade, n (%)TotalToxicity Grade, n (%)
Adverse Reactionn (%)3≥4n (%)3≥4
Note: Safety population: 147 patients in the subcutaneous treatment group and 74 patients in the intravenous treatment group who received at least one dose of study medication
*
Represents High Level Term Peripheral Neuropathies NEC

Blood and Lymphatic System Disorders

  Anemia

28 (19)

8 (5)

0

17 (23)

3 (4)

0

  Leukopenia

26 (18)

8 (5)

0

15 (20)

4 (5)

1 (1)

  Neutropenia

34 (23)

15 (10)

4 (3)

20 (27)

10 (14)

3 (4)

  Thrombocytopenia

44 (30)

7 (5)

5 (3)

25 (34)

7 (9)

5 (7)

Gastrointestinal Disorders

  Diarrhea

28 (19)

1 (1)

0

21 (28)

3 (4)

0

  Nausea

24 (16)

0

0

10 (14)

0

0

  Vomiting

13 (9)

3 (2)

0

8 (11)

0

0

General Disorders and Administration Site Conditions

  Asthenia

10 (7)

1 (1)

0

12 (16)

4 (5)

0

  Fatigue

11 (7)

3 (2)

0

11 (15)

3 (4)

0

  Pyrexia

18 (12)

0

0

6 (8)

0

0

Nervous System Disorders

  Neuralgia

34 (23)

5 (3)

0

17 (23)

7 (9)

0

  Peripheral neuropathies*

55 (37)

8 (5)

1 (1)

37 (50)

10 (14)

1 (1)

In general, safety data were similar for the subcutaneous and intravenous treatment groups. Differences were observed in the rates of some Grade ≥3 adverse reactions. Differences of ≥5% were reported in neuralgia (3% subcutaneous vs 9% intravenous), peripheral neuropathies (6% subcutaneous vs 15% intravenous), neutropenia (13% subcutaneous vs 18% intravenous), and thrombocytopenia (8% subcutaneous vs 16% intravenous).

A local reaction was reported in 6% of patients in the subcutaneous group, mostly redness. Only two (1%) patients were reported as having severe reactions, one case of pruritus and one case of redness. Local reactions led to reduction in injection concentration in one patient and drug discontinuation in one patient. Local reactions resolved in a median of six days.

Dose reductions occurred due to adverse reactions in 31% of patients in the subcutaneous treatment group compared with 43% of the intravenously-treated patients. The most common adverse reactions leading to a dose reduction included peripheral sensory neuropathy (17% in the subcutaneous treatment group compared with 31% in the intravenous treatment group); and neuralgia (11% in the subcutaneous treatment group compared with 19% in the intravenous treatment group).

Serious Adverse Reactions and Adverse Reactions Leading to Treatment Discontinuation in the Relapsed Multiple Myeloma Study of Bortezomib Subcutaneous vs Intravenous

The incidence of serious adverse reactions was similar for the subcutaneous treatment group (20%) and the intravenous treatment group (19%). The most commonly reported serious adverse reactions in the subcutaneous treatment arm were pneumonia and pyrexia (2% each). In the intravenous treatment group, the most commonly reported serious adverse reactions were pneumonia, diarrhea, and peripheral sensory neuropathy (3% each).

In the subcutaneous treatment group, 27 patients (18%) discontinued study treatment due to an adverse reaction compared with 17 patients (23%) in the intravenous treatment group. Among the 147 subcutaneously-treated patients, the most commonly reported adverse reactions leading to discontinuation were peripheral sensory neuropathy (5%) and neuralgia (5%). Among the 74 patients in the intravenous treatment group, the most commonly reported adverse reactions leading to treatment discontinuation were peripheral sensory neuropathy (9%) and neuralgia (9%).

Two patients (1%) in the subcutaneous treatment group and one (1%) patient in the intravenous treatment group died due to an adverse reaction during treatment. In the subcutaneous group the causes of death were one case of pneumonia and one case of sudden death. In the intravenous group the cause of death was coronary artery insufficiency.

Safety Experience from the Clinical Trial in Patients with Previously Untreated Mantle Cell Lymphoma

Table 12 describes safety data from 240 patients with previously untreated mantle cell lymphoma who received bortezomib (1.3 mg/m2) administered intravenously in combination with rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and prednisone (100 mg/m2) (VcR-CAP) in a prospective randomized study.

Infections were reported for 31% of patients in the VcR-CAP arm and 23% of the patients in the comparator (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) arm, including the predominant preferred term of pneumonia (VcR-CAP 8% vs R-CHOP 5%).

Table 12: Most Commonly Reported Adverse Reactions (≥5%) with Grades 3 and ≥4 Intensity in the Previously Untreated Mantle Cell Lymphoma Study
VcR-CAP
(N = 240)
R-CHOP
(N = 242)
Body SystemAllToxicity Grade 3Toxicity Grade ≥4AllToxicity Grade 3Toxicity Grade ≥4
  Adverse Reactionsn (%)n (%)n (%)n (%)n (%)n (%)
Key: R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; VcR-CAP = bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone.
*
Represents High Level Term Peripheral Neuropathies NEC.

Blood and Lymphatic System Disorders

  Neutropenia

209 (87)

32 (13)

168 (70)

172 (71)

31 (13)

125 (52)

  Leukopenia

116 (48)

34 (14)

69 (29)

87 (36)

39 (16)

27 (11)

  Anemia

106 (44)

27 (11)

4 (2)

71 (29)

23 (10)

4 (2)

  Thrombocytopenia

172 (72)

59 (25)

76 (32)

42 (17)

9 (4)

3 (1)

  Febrile neutropenia

41 (17)

24 (10)

12 (5)

33 (14)

17 (7)

15 (6)

  Lymphopenia

68 (28)

25 (10)

36 (15)

28 (12)

15 (6)

2 (1)

Nervous System Disorders

  Peripheral

    neuropathy*

71 (30)

17 (7)

1 (<1)

65 (27)

10 (4)

0

  Hypoesthesia

14 (6)

3 (1)

0

13 (5)

0

0

  Paresthesia

14 (6)

2 (1)

0

11 (5)

0

0

  Neuralgia

25 (10)

9 (4)

0

1 (<1)

0

0

General Disorders and Administration Site Conditions

  Fatigue

43 (18)

11 (5)

1 (<1)

38 (16)

5 (2)

0

  Pyrexia

48 (20)

7 (3)

0

23 (10)

5 (2)

0

  Asthenia

29 (12)

4 (2)

1 (<1)

18 (7)

1 (<1)

0

  Edema peripheral

16 (7)

1 (<1)

0

13 (5)

0

0

Gastrointestinal Disorders

  Nausea

54 (23)

1 (<1)

0

28 (12)

0

0

  Constipation

42 (18)

1 (<1)

0

22 (9)

2 (1)

0

  Stomatitis

20 (8)

2 (1)

0

19 (8)

0

1 (<1)

  Diarrhea

59 (25)

11 (5)

0

11 (5)

3 (1)

1 (<1)

  Vomiting

24 (10)

1 (<1)

0

8 (3)

0

0

  Abdominal distension

13 (15)

0

0

4 (2)

0

0

Infections and Infestations

  Pneumonia

20 (8)

8 (3)

5 (2)

11 (5)

5 (2)

3 (1)

Skin and Subcutaneous Tissue Disorders

  Alopecia

31 (13)

1 (<1)

1 (<1)

33 (14)

4 (2)

0

Metabolism and Nutrition Disorders

  Hyperglycemia

10 (4)

1 (<1)

0

17 (7)

10 (4)

0

  Decreased appetite

36 (15)

2 (1)

0

15 (6)

1 (<1)

0

Vascular Disorders

  Hypertension

15 (6)

1 (<1)

0

3 (1)

0

0

Psychiatric Disorders

  Insomnia

16 (7)

1 (<1)

0

8 (3)

0

0

The incidence of herpes zoster reactivation was 4.6% in the VcR-CAP arm and 0.8% in the R-CHOP arm. Antiviral prophylaxis was mandated by protocol amendment.

The incidences of Grade ≥3 bleeding events were similar between the two arms (four patients in the VcR-CAP arm and three patients in the R-CHOP arm). All of the Grade ≥3 bleeding events resolved without sequelae in the VcR-CAP arm.

Adverse reactions leading to discontinuation occurred in 8% of patients in VcR-CAP group and 6% of patients in R-CHOP group. In the VcR-CAP group, the most commonly reported adverse reaction leading to discontinuation was peripheral sensory neuropathy (1%; three patients). The most commonly reported adverse reaction leading to discontinuation in the R-CHOP group was febrile neutropenia (<1%; two patients).

Integrated Summary of Safety (Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma)

Safety data from Phase 2 and 3 studies of single agent bortezomib 1.3 mg/m2/dose twice weekly for two weeks followed by a ten day rest period in 1163 patients with previously-treated multiple myeloma (N=1008) and previously-treated mantle cell lymphoma (N=155) were integrated and tabulated. This analysis does not include data from the Phase 3 open-label study of bortezomib subcutaneous vs intravenous in relapsed multiple myeloma. In the integrated studies, the safety profile of bortezomib was similar in patients with multiple myeloma and mantle cell lymphoma.

In the integrated analysis, the most commonly reported (>20%) adverse reactions were nausea (49%), diarrhea (46%), asthenic conditions including fatigue (41%) and weakness (11%), peripheral neuropathies (38%), thrombocytopenia (32%), vomiting (28%), constipation (25%), and pyrexia (21%). Eleven percent (11%) of patients experienced at least one episode of ≥Grade 4 toxicity, most commonly thrombocytopenia (4%) and neutropenia (2%).

In the Phase 2 relapsed multiple myeloma clinical trials of bortezomib administered intravenously, local skin irritation was reported in 5% of patients, but extravasation of bortezomib was not associated with tissue damage.

Serious Adverse Reactions and Adverse Reactions Leading to Treatment Discontinuation in the Integrated Summary of Safety

A total of 26% of patients experienced a serious adverse reaction during the studies. The most commonly reported serious adverse reactions included diarrhea, vomiting and pyrexia (3% each), nausea, dehydration, and thrombocytopenia (2% each) and pneumonia, dyspnea, peripheral neuropathies, and herpes zoster (1% each).

Adverse reactions leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), and fatigue, thrombocytopenia, and diarrhea (2% each).

In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis.

Most Commonly Reported Adverse Reactions in the Integrated Summary of Safety

The most common adverse reactions are shown in Table 13. All adverse reactions occurring at ≥10% are included. In the absence of a randomized comparator arm, it is often not possible to distinguish between adverse events that are drug-caused and those that reflect the patient's underlying disease. Please see the discussion of specific adverse reactions that follows.

Table 13: Most Commonly Reported (≥ 10% Overall) Adverse Reactions in Integrated Analyses of Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma Studies Using the 1.3 mg/m2 Dose (N=1163)
All Patients
(N=1163)
Multiple Myeloma
(N=1008)
Mantle Cell Lymphoma
(N=155)
Adverse ReactionsAll≥Grade 3All≥Grade 3All≥Grade 3
*
Represents High Level Term Peripheral Neuropathies NEC

Nausea

567 (49)

36 (3)

511 (51)

32 (3)

56 (36)

4 (3)

Diarrhea NOS

530 (46)

83 (7)

470 (47)

72 (7)

60 (39)

11 (7)

Fatigue

477 (41)

86 (7)

396 (39)

71 (7)

81 (52)

15 (10)

Peripheral neuropathies*

443 (38)

129 (11)

359 (36)

110 (11)

84 (54)

19 (12)

Thrombocytopenia

369 (32)

295 (25)

344 (34)

283 (28)

25 (16)

12 (8)

Vomiting NOS

321 (28)

44 (4)

286 (28)

40 (4)

35 (23)

4 (3)

Constipation

296 (25)

17 (1)

244 (24)

14 (1)

52 (34)

3 (2)

Pyrexia

249 (21)

16 (1)

233 (23)

15 (1)

16 (10)

1 (<1)

Anorexia

227 (20)

19 (2)

205 (20)

16 (2)

22 (14)

3 (2)

Anemia NOS

209 (18)

65 (6)

190 (19)

63 (6)

19 (12)

2 (1)

Headache NOS

175 (15)

8 (<1)

160 (16)

8 (<1)

15 (10)

0

Neutropenia

172 (15)

121 (10)

164 (16)

117 (12)

8 (5)

4 (3)

Rash NOS

156 (13)

8 (<1)

120 (12)

4 (<1)

36 (23)

4 (3)

Paresthesia

147 (13)

9 (<1)

136 (13)

8 (<1)

11 (7)

1 (<1)

Dizziness (excl vertigo)

129 (11)

13 (1)

101 (10)

9 (<1)

28 (18)

4 (3)

Weakness

124 (11)

31 (3)

106 (11)

28 (3)

18 (12)

3 (2)

Description of Selected Adverse Reactions from the Integrated Phase 2 and Phase 3 Relapsed Multiple Myeloma and Phase 2 Relapsed Mantle Cell Lymphoma Studies

Gastrointestinal Toxicity

A total of 75% of patients experienced at least one gastrointestinal disorder. The most common gastrointestinal disorders included nausea, diarrhea, constipation, vomiting, and appetite decreased. Other gastrointestinal disorders included dyspepsia and dysgeusia. Grade 3 adverse reactions occurred in 14% of patients; ≥Grade 4 adverse reactions were ≤1%. Gastrointestinal adverse reactions were considered serious in 7% of patients. Four percent (4%) of patients discontinued due to a gastrointestinal adverse reaction. Nausea was reported more often in patients with multiple myeloma (51%) compared to patients with mantle cell lymphoma (36%).

Thrombocytopenia

Across the studies, bortezomib-associated thrombocytopenia was characterized by a decrease in platelet count during the dosing period (Days 1 to 11) and a return toward baseline during the ten day rest period during each treatment cycle. Overall, thrombocytopenia was reported in 32% of patients. Thrombocytopenia was Grade 3 in 22%, ≥Grade 4 in 4%, and serious in 2% of patients, and the reaction resulted in bortezomib discontinuation in 2% of patients [see Warnings and Precautions (5.7)]. Thrombocytopenia was reported more often in patients with multiple myeloma (34%) compared to patients with mantle cell lymphoma (16%). The incidence of ≥Grade 3 thrombocytopenia also was higher in patients with multiple myeloma (28%) compared to patients with mantle cell lymphoma (8%).

Peripheral Neuropathy

Overall, peripheral neuropathies occurred in 38% of patients. Peripheral neuropathy was Grade 3 for 11% of patients and ≥Grade 4 for <1% of patients. Eight percent (8%) of patients discontinued bortezomib due to peripheral neuropathy. The incidence of peripheral neuropathy was higher among patients with mantle cell lymphoma (54%) compared to patients with multiple myeloma (36%).

In the bortezomib vs dexamethasone Phase 3 relapsed multiple myeloma study, among the 62 bortezomib-treated patients who experienced ≥Grade 2 peripheral neuropathy and had dose adjustments, 48% had improved or resolved with a median of 3.8 months from first onset.

In the Phase 2 relapsed multiple myeloma studies, among the 30 patients who experienced Grade 2 peripheral neuropathy resulting in discontinuation or who experienced ≥Grade 3 peripheral neuropathy, 73% reported improvement or resolution with a median time of 47 days to improvement of one grade or more from the last dose of bortezomib.

Hypotension

The incidence of hypotension (postural, orthostatic and hypotension NOS) was 8% in patients treated with bortezomib. Hypotension was Grade 1 or 2 in the majority of patients and Grade 3 in 2% and ≥Grade 4 in <1%. Two percent (2%) of patients had hypotension reported as a serious adverse reaction, and 1% discontinued due to hypotension. The incidence of hypotension was similar in patients with multiple myeloma (8%) and those with mantle cell lymphoma (9%). In addition, <1% of patients experienced hypotension associated with a syncopal reaction.

Neutropenia

Neutrophil counts decreased during the bortezomib dosing period (Days 1 to 11) and returned toward baseline during the ten day rest period during each treatment cycle. Overall, neutropenia occurred in 15% of patients and was Grade 3 in 8% of patients and ≥Grade 4 in 2%. Neutropenia was reported as a serious adverse reaction in <1% of patients and <1% of patients discontinued due to neutropenia. The incidence of neutropenia was higher in patients with multiple myeloma (16%) compared to patients with mantle cell lymphoma (5%). The incidence of ≥Grade 3 neutropenia also was higher in patients with multiple myeloma (12%) compared to patients with mantle cell lymphoma (3%).

Asthenic Conditions (Fatigue, Malaise, Weakness, Asthenia)

Asthenic conditions were reported in 54% of patients. Fatigue was reported as Grade 3 in 7% and ≥Grade 4 in <1% of patients. Asthenia was reported as Grade 3 in 2% and ≥Grade 4 in <1% of patients. Two percent (2%) of patients discontinued treatment due to fatigue and <1% due to weakness and asthenia. Asthenic conditions were reported in 53% of patients with multiple myeloma and 59% of patients with mantle cell lymphoma.

Pyrexia

Pyrexia (>38°C) was reported as an adverse reaction for 21% of patients. The reaction was Grade 3 in 1% and ≥Grade 4 in <1%. Pyrexia was reported as a serious adverse reaction in 3% of patients and led to bortezomib discontinuation in <1% of patients. The incidence of pyrexia was higher among patients with multiple myeloma (23%) compared to patients with mantle cell lymphoma (10%). The incidence of ≥Grade 3 pyrexia was 1% in patients with multiple myeloma and <1% in patients with mantle cell lymphoma.

Herpes Virus Infection

Consider using antiviral prophylaxis in subjects being treated with Bortezomib for Injection. In the randomized studies in previously untreated and relapsed multiple myeloma, herpes zoster reactivation was more common in subjects treated with bortezomib (ranging between 6% to 11%) than in the control groups (3% to 4%). Herpes simplex was seen in 1% to 3% in subjects treated with bortezomib and 1% to 3% in the control groups. In the previously untreated multiple myeloma study, herpes zoster virus reactivation in the bortezomib, melphalan and prednisone arm was less common in subjects receiving prophylactic antiviral therapy (3%) than in subjects who did not receive prophylactic antiviral therapy (17%).

Retreatment in Relapsed Multiple Myeloma

A single-arm trial was conducted in 130 patients with relapsed multiple myeloma to determine the efficacy and safety of retreatment with intravenous bortezomib. The safety profile of patients in this trial is consistent with the known safety profile of bortezomib-treated patients with relapsed multiple myeloma as demonstrated in Tables 10, 11, and 13; no cumulative toxicities were observed upon retreatment. The most common adverse drug reaction was thrombocytopenia which occurred in 52% of the patients. The incidence of ≥Grade 3 thrombocytopenia was 24%. Peripheral neuropathy occurred in 28% of patients, with the incidence of ≥Grade 3 peripheral neuropathy reported at 6%. The incidence of serious adverse reactions was 12.3%. The most commonly reported serious adverse reactions were thrombocytopenia (3.8%), diarrhea (2.3%), and herpes zoster and pneumonia (1.5% each).

Adverse reactions leading to discontinuation occurred in 13% of patients. The reasons for discontinuation included peripheral neuropathy (5%) and diarrhea (3%).

Two deaths considered to be bortezomib-related occurred within 30 days of the last bortezomib dose; one in a patient with cerebrovascular accident and one in a patient with sepsis.

Additional Adverse Reactions from Clinical Studies

The following clinically important serious adverse reactions that are not described above have been reported in clinical trials in patients treated with bortezomib administered as monotherapy or in combination with other chemotherapeutics. These studies were conducted in patients with hematological malignancies and in solid tumors.

Blood and Lymphatic System Disorders: Anemia, disseminated intravascular coagulation, febrile neutropenia, lymphopenia, leukopenia

Cardiac Disorders: Angina pectoris, atrial fibrillation aggravated, atrial flutter, bradycardia, sinus arrest, cardiac amyloidosis, complete atrioventricular block, myocardial ischemia, myocardial infarction, pericarditis, pericardial effusion, Torsades de pointes, ventricular tachycardia

Ear and Labyrinth Disorders: Hearing impaired, vertigo

Eye Disorders: Diplopia and blurred vision, conjunctival infection, irritation

Gastrointestinal Disorders: Abdominal pain, ascites, dysphagia, fecal impaction, gastroenteritis, gastritis hemorrhagic, hematemesis, hemorrhagic duodenitis, ileus paralytic, large intestinal obstruction, paralytic intestinal obstruction, peritonitis, small intestinal obstruction, large intestinal perforation, stomatitis, melena, pancreatitis acute, oral mucosal petechiae, gastroesophageal reflux

General Disorders and Administration Site Conditions: Chills, edema, edema peripheral, injection site erythema, neuralgia, injection site pain, irritation, malaise, phlebitis

Hepatobiliary Disorders: Cholestasis, hepatic hemorrhage, hyperbilirubinemia, portal vein thrombosis, hepatitis, liver failure

Immune System Disorders: Anaphylactic reaction, drug hypersensitivity, immune complex mediated hypersensitivity, angioedema, laryngeal edema

Infections and Infestations: Aspergillosis, bacteremia, bronchitis, urinary tract infection, herpes viral infection, listeriosis, nasopharyngitis, pneumonia, respiratory tract infection, septic shock, toxoplasmosis, oral candidiasis, sinusitis, catheter-related infection

Injury, Poisoning and Procedural Complications: Catheter-related complication, skeletal fracture, subdural hematoma

Investigations: Weight decreased

Metabolism and Nutrition Disorders: Dehydration, hypocalcemia, hyperuricemia, hypokalemia, hyperkalemia, hyponatremia, hypernatremia

Musculoskeletal and Connective Tissue Disorders: Arthralgia, back pain, bone pain, myalgia, pain in extremity

Nervous System Disorders: Ataxia, coma, dizziness, dysarthria, dysesthesia, dysautonomia, encephalopathy, cranial palsy, grand mal convulsion, headache, hemorrhagic stroke, motor dysfunction, neuralgia, spinal cord compression, paralysis, postherpetic neuralgia, transient ischemic attack

Psychiatric Disorders: Agitation, anxiety, confusion, insomnia, mental status change, psychotic disorder, suicidal ideation

Renal and Urinary Disorders: Calculus renal, bilateral hydronephrosis, bladder spasm, hematuria, hemorrhagic cystitis, urinary incontinence, urinary retention, renal failure (acute and chronic), glomerular nephritis proliferative

Respiratory, Thoracic and Mediastinal Disorders: Acute respiratory distress syndrome, aspiration pneumonia, atelectasis, chronic obstructive airways disease exacerbated, cough, dysphagia, dyspnea, dyspnea exertional, epistaxis, hemoptysis, hypoxia, lung infiltration, pleural effusion, pneumonitis, respiratory distress, pulmonary hypertension

Skin and Subcutaneous Tissue Disorders: Urticaria, face edema, rash (which may be pruritic), leukocytoclastic vasculitis, pruritus

Vascular Disorders: Cerebrovascular accident, cerebral hemorrhage, deep venous thrombosis, hypertension, peripheral embolism, pulmonary embolism, pulmonary hypertension

6.2 Postmarketing Experience

The following adverse reactions have been identified from the worldwide postmarketing experience with bortezomib. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

Cardiac Disorders: Cardiac tamponade

Ear and Labyrinth Disorders: Deafness bilateral

Eye Disorders: Optic neuropathy, blindness, chalazion/blepharitis

Gastrointestinal Disorders: Ischemic colitis

Infections and Infestations: Progressive multifocal leukoencephalopathy (PML), ophthalmic herpes, herpes meningoencephalitis

Nervous System Disorders: Posterior reversible encephalopathy syndrome (PRES, formerly RPLS), Guillain-Barré syndrome, demyelinating polyneuropathy

Respiratory, Thoracic and Mediastinal Disorders: Acute diffuse infiltrative pulmonary disease

Skin and Subcutaneous Tissue Disorders: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), acute febrile neutrophilic dermatosis (Sweet's syndrome)

Find bortezomib injection 1 MG and 2.5 MG VIAL medical information:

Find bortezomib injection 1 MG and 2.5 MG VIAL medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

bortezomib injection 1 MG and 2.5 MG VIAL Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Adverse Reactions

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are also discussed in other sections of the labeling:

Peripheral Neuropathy [see Warnings and Precautions (5.1)]
Hypotension [see Warnings and Precautions (5.2)]
Cardiac Toxicity [see Warnings and Precautions (5.3)]
Pulmonary Toxicity [see Warnings and Precautions (5.4)]
Posterior Reversible Encephalopathy Syndrome (PRES) [see Warnings and Precautions (5.5)]
Gastrointestinal Toxicity [see Warnings and Precautions (5.6)]
Thrombocytopenia/Neutropenia [see Warnings and Precautions (5.7)]
Tumor Lysis Syndrome [see Warnings and Precautions (5.8)]
Hepatic Toxicity [see Warnings and Precautions (5.9)]
Thrombotic Microangiopathy [see Warnings and Precautions (5.10)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Summary of Clinical Trial in Patients with Previously Untreated Multiple Myeloma

Table 9 describes safety data from 340 patients with previously untreated multiple myeloma who received bortezomib (1.3 mg/m2) administered intravenously in combination with melphalan (9 mg/m2) and prednisone (60 mg/m2) in a prospective randomized study.

The safety profile of bortezomib in combination with melphalan/prednisone is consistent with the known safety profiles of both bortezomib and melphalan/prednisone.

Table 9: Most Commonly Reported Adverse Reactions (≥10% in the Bortezomib, Melphalan and Prednisone Arm) with Grades 3 and ≥4 Intensity in the Previously Untreated Multiple Myeloma Study
Bortezomib, Melphalan and Prednisone
(n = 340)
Melphalan and Prednisone
(n = 337)
Body SystemTotalToxicity Grade, n (%)TotalToxicity Grade, n (%)
Adverse Reactionn (%)3≥4n (%)3≥4
*
Represents High Level Term Peripheral Neuropathies NEC

Blood and Lymphatic System Disorders

  Thrombocytopenia

164 (48)

60 (18)

57 (17)

140 (42)

48 (14)

39 (12)

  Neutropenia

160 (47)

101 (30)

33 (10)

143 (42)

77 (23)

42 (12)

  Anemia

109 (32)

41 (12)

4 (1)

156 (46)

61 (18)

18 (5)

  Leukopenia

108 (32)

64 (19)

8 (2)

93 (28)

53 (16)

11 (3)

  Lymphopenia

78 (23)

46 (14)

17 (5)

51 (15)

26 (8)

7 (2)

Gastrointestinal Disorders

  Nausea

134 (39)

10 (3)

0

70 (21)

1 (<1)

0

  Diarrhea

119 (35)

19 (6)

2 (1)

20 (6)

1 (<1)

0

  Vomiting

87 (26)

13 (4)

0

41 (12)

2 (1)

0

  Constipation

77 (23)

2 (1)

0

14 (4)

0

0

  Abdominal pain upper

34 (10)

1 (<1)

0

20 (6)

0

0

Nervous System Disorders

  Peripheral neuropathy*

156 (46)

42 (12)

2 (1)

4 (1)

0

0

  Neuralgia

117 (34)

27 (8)

2 (1)

1 (<1)

0

0

  Paresthesia

42 (12)

6 (2)

0

4 (1)

0

0

General Disorders and Administration Site Conditions

  Fatigue

85 (25)

19 (6)

2 (1)

48 (14)

4 (1)

0

  Asthenia

54 (16)

18 (5)

0

23 (7)

3 (1)

0

  Pyrexia

53 (16)

4 (1)

0

19 (6)

1 (<1)

1 (<1)

Infections and Infestations

  Herpes Zoster

39 (11)

11 (3)

0

9 (3)

4 (1)

0

Metabolism and Nutrition Disorders

  Anorexia

64 (19)

6 (2)

0

19 (6)

0

0

Skin and Subcutaneous Tissue Disorders

  Rash

38 (11)

2 (1)

0

7 (2)

0

0

Psychiatric Disorders

  Insomnia

35 (10)

1 (<1)

0

21 (6)

0

0

Relapsed Multiple Myeloma Randomized Study of Bortezomib vs Dexamethasone

The safety data described below and in Table 10 reflect exposure to either bortezomib (n=331) or dexamethasone (n=332) in a study of patients with relapsed multiple myeloma. Bortezomib was administered intravenously at doses of 1.3 mg/m2 twice weekly for two out of three weeks (21 day cycle). After eight 21 day cycles patients continued therapy for three 35 day cycles on a weekly schedule. Duration of treatment was up to 11 cycles (nine months) with a median duration of six cycles (4.1 months). For inclusion in the trial, patients must have had measurable disease and one to three prior therapies. There was no upper age limit for entry. Creatinine clearance could be as low as 20 mL/min and bilirubin levels as high as 1.5 times the upper limit of normal. The overall frequency of adverse reactions was similar in men and women, and in patients <65 and ≥65 years of age. Most patients were Caucasian [see Clinical Studies (14.1)].

Among the 331 bortezomib-treated patients, the most commonly reported (>20%) adverse reactions overall were nausea (52%), diarrhea (52%), fatigue (39%), peripheral neuropathies (35%), thrombocytopenia (33%), constipation (30%), vomiting (29%), and anorexia (21%). The most commonly reported (>20%) adverse reaction reported among the 332 patients in the dexamethasone group was fatigue (25%). Eight percent (8%) of patients in the bortezomib-treated arm experienced a Grade 4 adverse reaction; the most common reactions were thrombocytopenia (4%) and neutropenia (2%). Nine percent (9%) of dexamethasone-treated patients experienced a Grade 4 adverse reaction. All individual dexamethasone-related Grade 4 adverse reactions were less than 1%.

Serious Adverse Reactions and Adverse Reactions Leading to Treatment Discontinuation in the Relapsed Multiple Myeloma Study of Bortezomib vs Dexamethasone

Serious adverse reactions are defined as any reaction that results in death, is life-threatening, requires hospitalization or prolongs a current hospitalization, results in a significant disability, or is deemed to be an important medical event. A total of 80 (24%) patients from the bortezomib treatment arm experienced a serious adverse reaction during the study, as did 83 (25%) dexamethasone-treated patients. The most commonly reported serious adverse reactions in the bortezomib treatment arm were diarrhea (3%), dehydration, herpes zoster, pyrexia, nausea, vomiting, dyspnea, and thrombocytopenia (2% each). In the dexamethasone treatment group, the most commonly reported serious adverse reactions were pneumonia (4%), hyperglycemia (3%), pyrexia, and psychotic disorder (2% each).

A total of 145 patients, including 84 (25%) of 331 patients in the bortezomib treatment group and 61 (18%) of 332 patients in the dexamethasone treatment group were discontinued from treatment due to adverse reactions. Among the 331 bortezomib-treated patients, the most commonly reported adverse reaction leading to discontinuation was peripheral neuropathy (8%). Among the 332 patients in the dexamethasone group, the most commonly reported adverse reactions leading to treatment discontinuation were psychotic disorder and hyperglycemia (2% each).

Four deaths were considered to be bortezomib-related in this relapsed multiple myeloma study: one case each of cardiogenic shock, respiratory insufficiency, congestive heart failure and cardiac arrest. Four deaths were considered dexamethasone-related: two cases of sepsis, one case of bacterial meningitis, and one case of sudden death at home.

Most Commonly Reported Adverse Reactions in the Relapsed Multiple Myeloma Study of Bortezomib vs Dexamethasone

The most common adverse reactions from the relapsed multiple myeloma study are shown in Table 10. All adverse reactions with incidence ≥10% in the bortezomib arm are included.

Table 10: Most Commonly Reported Adverse Reactions (≥10% in Bortezomib Arm), with Grades 3 and 4 Intensity in the Relapsed Multiple Myeloma Study of Bortezomib vs Dexamethasone (N=663)
Bortezomib
(N = 331)
Dexamethasone
(N = 332)
Adverse ReactionsAllGrade 3Grade 4AllGrade 3Grade 4
*
Represents High Level Term Peripheral Neuropathies NEC

Any Adverse Reactions

324 (98)

193 (58)

28 (8)

297 (89)

110 (33)

29 (9)

Nausea

172 (52)

8 (2)

0

31 (9)

0

0

Diarrhea NOS

171 (52)

22 (7)

0

36 (11)

2 (<1)

0

Fatigue

130 (39)

15 (5)

0

82 (25)

8 (2)

0

Peripheral neuropathies*

115 (35)

23 (7)

2 (<1)

14 (4)

0

1 (< 1)

Thrombocytopenia

109 (33)

80 (24)

12 (4)

11 (3)

5 (2)

1 (< 1)

Constipation

99 (30)

6 (2)

0

27 (8)

1 (<1)

0

Vomiting NOS

96 (29)

8 (2)

0

10 (3)

1 (<1)

0

Anorexia

68 (21)

8 (2)

0

8 (2)

1 (<1)

0

Pyrexia

66 (20)

2 (<1)

0

21 (6)

3 (<1)

1 (< 1)

Paresthesia

64 (19)

5 (2)

0

24 (7)

0

0

Anemia NOS

63 (19)

20 (6)

1 (<1)

21 (6)

8 (2)

0

Headache NOS

62 (19)

3 (<1)

0

23 (7)

1 (<1)

0

Neutropenia

58 (18)

37 (11)

8 (2)

1 (<1)

1 (<1)

0

Rash NOS

43 (13)

3 (<1)

0

7 (2)

0

0

Appetite decreased NOS

36 (11)

0

0

12 (4)

0

0

Dyspnea NOS

35 (11)

11 (3)

1 (<1)

37 (11)

7 (2)

1 (< 1)

Abdominal pain NOS

35 (11)

5 (2)

0

7 (2)

0

0

Weakness

34 (10)

10 (3)

0

28 (8)

8 (2)

0

Safety Experience from the Phase 2 Open-Label Extension Study in Relapsed Multiple Myeloma

In the Phase 2 extension study of 63 patients, no new cumulative or new long-term toxicities were observed with prolonged bortezomib treatment. These patients were treated for a total of 5.3 to 23 months, including time on bortezomib in the prior bortezomib study [see Clinical Studies (14.1)].

Safety Experience from the Phase 3 Open-Label Study of Bortezomib Subcutaneous vs Intravenous in Relapsed Multiple Myeloma

The safety and efficacy of bortezomib administered subcutaneously were evaluated in one Phase 3 study at the recommended dose of 1.3 mg/m2. This was a randomized, comparative study of bortezomib subcutaneous vs intravenous in 222 patients with relapsed multiple myeloma. The safety data described below and in Table 11 reflect exposure to either bortezomib subcutaneous (N=147) or bortezomib intravenous (N=74) [see Clinical Studies (14.1)].

Table 11: Most Commonly Reported Adverse Reactions (≥10%), with Grade 3 and ≥4 Intensity in the Relapsed Multiple Myeloma Study (N=221) of Bortezomib Subcutaneous vs Intravenous
Subcutaneous
(N = 147)
Intravenous
(N = 74)
Body SystemTotalToxicity Grade, n (%)TotalToxicity Grade, n (%)
Adverse Reactionn (%)3≥4n (%)3≥4
Note: Safety population: 147 patients in the subcutaneous treatment group and 74 patients in the intravenous treatment group who received at least one dose of study medication
*
Represents High Level Term Peripheral Neuropathies NEC

Blood and Lymphatic System Disorders

  Anemia

28 (19)

8 (5)

0

17 (23)

3 (4)

0

  Leukopenia

26 (18)

8 (5)

0

15 (20)

4 (5)

1 (1)

  Neutropenia

34 (23)

15 (10)

4 (3)

20 (27)

10 (14)

3 (4)

  Thrombocytopenia

44 (30)

7 (5)

5 (3)

25 (34)

7 (9)

5 (7)

Gastrointestinal Disorders

  Diarrhea

28 (19)

1 (1)

0

21 (28)

3 (4)

0

  Nausea

24 (16)

0

0

10 (14)

0

0

  Vomiting

13 (9)

3 (2)

0

8 (11)

0

0

General Disorders and Administration Site Conditions

  Asthenia

10 (7)

1 (1)

0

12 (16)

4 (5)

0

  Fatigue

11 (7)

3 (2)

0

11 (15)

3 (4)

0

  Pyrexia

18 (12)

0

0

6 (8)

0

0

Nervous System Disorders

  Neuralgia

34 (23)

5 (3)

0

17 (23)

7 (9)

0

  Peripheral neuropathies*

55 (37)

8 (5)

1 (1)

37 (50)

10 (14)

1 (1)

In general, safety data were similar for the subcutaneous and intravenous treatment groups. Differences were observed in the rates of some Grade ≥3 adverse reactions. Differences of ≥5% were reported in neuralgia (3% subcutaneous vs 9% intravenous), peripheral neuropathies (6% subcutaneous vs 15% intravenous), neutropenia (13% subcutaneous vs 18% intravenous), and thrombocytopenia (8% subcutaneous vs 16% intravenous).

A local reaction was reported in 6% of patients in the subcutaneous group, mostly redness. Only two (1%) patients were reported as having severe reactions, one case of pruritus and one case of redness. Local reactions led to reduction in injection concentration in one patient and drug discontinuation in one patient. Local reactions resolved in a median of six days.

Dose reductions occurred due to adverse reactions in 31% of patients in the subcutaneous treatment group compared with 43% of the intravenously-treated patients. The most common adverse reactions leading to a dose reduction included peripheral sensory neuropathy (17% in the subcutaneous treatment group compared with 31% in the intravenous treatment group); and neuralgia (11% in the subcutaneous treatment group compared with 19% in the intravenous treatment group).

Serious Adverse Reactions and Adverse Reactions Leading to Treatment Discontinuation in the Relapsed Multiple Myeloma Study of Bortezomib Subcutaneous vs Intravenous

The incidence of serious adverse reactions was similar for the subcutaneous treatment group (20%) and the intravenous treatment group (19%). The most commonly reported serious adverse reactions in the subcutaneous treatment arm were pneumonia and pyrexia (2% each). In the intravenous treatment group, the most commonly reported serious adverse reactions were pneumonia, diarrhea, and peripheral sensory neuropathy (3% each).

In the subcutaneous treatment group, 27 patients (18%) discontinued study treatment due to an adverse reaction compared with 17 patients (23%) in the intravenous treatment group. Among the 147 subcutaneously-treated patients, the most commonly reported adverse reactions leading to discontinuation were peripheral sensory neuropathy (5%) and neuralgia (5%). Among the 74 patients in the intravenous treatment group, the most commonly reported adverse reactions leading to treatment discontinuation were peripheral sensory neuropathy (9%) and neuralgia (9%).

Two patients (1%) in the subcutaneous treatment group and one (1%) patient in the intravenous treatment group died due to an adverse reaction during treatment. In the subcutaneous group the causes of death were one case of pneumonia and one case of sudden death. In the intravenous group the cause of death was coronary artery insufficiency.

Safety Experience from the Clinical Trial in Patients with Previously Untreated Mantle Cell Lymphoma

Table 12 describes safety data from 240 patients with previously untreated mantle cell lymphoma who received bortezomib (1.3 mg/m2) administered intravenously in combination with rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and prednisone (100 mg/m2) (VcR-CAP) in a prospective randomized study.

Infections were reported for 31% of patients in the VcR-CAP arm and 23% of the patients in the comparator (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) arm, including the predominant preferred term of pneumonia (VcR-CAP 8% vs R-CHOP 5%).

Table 12: Most Commonly Reported Adverse Reactions (≥5%) with Grades 3 and ≥4 Intensity in the Previously Untreated Mantle Cell Lymphoma Study
VcR-CAP
(N = 240)
R-CHOP
(N = 242)
Body SystemAllToxicity Grade 3Toxicity Grade ≥4AllToxicity Grade 3Toxicity Grade ≥4
  Adverse Reactionsn (%)n (%)n (%)n (%)n (%)n (%)
Key: R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; VcR-CAP = bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone.
*
Represents High Level Term Peripheral Neuropathies NEC.

Blood and Lymphatic System Disorders

  Neutropenia

209 (87)

32 (13)

168 (70)

172 (71)

31 (13)

125 (52)

  Leukopenia

116 (48)

34 (14)

69 (29)

87 (36)

39 (16)

27 (11)

  Anemia

106 (44)

27 (11)

4 (2)

71 (29)

23 (10)

4 (2)

  Thrombocytopenia

172 (72)

59 (25)

76 (32)

42 (17)

9 (4)

3 (1)

  Febrile neutropenia

41 (17)

24 (10)

12 (5)

33 (14)

17 (7)

15 (6)

  Lymphopenia

68 (28)

25 (10)

36 (15)

28 (12)

15 (6)

2 (1)

Nervous System Disorders

  Peripheral

    neuropathy*

71 (30)

17 (7)

1 (<1)

65 (27)

10 (4)

0

  Hypoesthesia

14 (6)

3 (1)

0

13 (5)

0

0

  Paresthesia

14 (6)

2 (1)

0

11 (5)

0

0

  Neuralgia

25 (10)

9 (4)

0

1 (<1)

0

0

General Disorders and Administration Site Conditions

  Fatigue

43 (18)

11 (5)

1 (<1)

38 (16)

5 (2)

0

  Pyrexia

48 (20)

7 (3)

0

23 (10)

5 (2)

0

  Asthenia

29 (12)

4 (2)

1 (<1)

18 (7)

1 (<1)

0

  Edema peripheral

16 (7)

1 (<1)

0

13 (5)

0

0

Gastrointestinal Disorders

  Nausea

54 (23)

1 (<1)

0

28 (12)

0

0

  Constipation

42 (18)

1 (<1)

0

22 (9)

2 (1)

0

  Stomatitis

20 (8)

2 (1)

0

19 (8)

0

1 (<1)

  Diarrhea

59 (25)

11 (5)

0

11 (5)

3 (1)

1 (<1)

  Vomiting

24 (10)

1 (<1)

0

8 (3)

0

0

  Abdominal distension

13 (15)

0

0

4 (2)

0

0

Infections and Infestations

  Pneumonia

20 (8)

8 (3)

5 (2)

11 (5)

5 (2)

3 (1)

Skin and Subcutaneous Tissue Disorders

  Alopecia

31 (13)

1 (<1)

1 (<1)

33 (14)

4 (2)

0

Metabolism and Nutrition Disorders

  Hyperglycemia

10 (4)

1 (<1)

0

17 (7)

10 (4)

0

  Decreased appetite

36 (15)

2 (1)

0

15 (6)

1 (<1)

0

Vascular Disorders

  Hypertension

15 (6)

1 (<1)

0

3 (1)

0

0

Psychiatric Disorders

  Insomnia

16 (7)

1 (<1)

0

8 (3)

0

0

The incidence of herpes zoster reactivation was 4.6% in the VcR-CAP arm and 0.8% in the R-CHOP arm. Antiviral prophylaxis was mandated by protocol amendment.

The incidences of Grade ≥3 bleeding events were similar between the two arms (four patients in the VcR-CAP arm and three patients in the R-CHOP arm). All of the Grade ≥3 bleeding events resolved without sequelae in the VcR-CAP arm.

Adverse reactions leading to discontinuation occurred in 8% of patients in VcR-CAP group and 6% of patients in R-CHOP group. In the VcR-CAP group, the most commonly reported adverse reaction leading to discontinuation was peripheral sensory neuropathy (1%; three patients). The most commonly reported adverse reaction leading to discontinuation in the R-CHOP group was febrile neutropenia (<1%; two patients).

Integrated Summary of Safety (Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma)

Safety data from Phase 2 and 3 studies of single agent bortezomib 1.3 mg/m2/dose twice weekly for two weeks followed by a ten day rest period in 1163 patients with previously-treated multiple myeloma (N=1008) and previously-treated mantle cell lymphoma (N=155) were integrated and tabulated. This analysis does not include data from the Phase 3 open-label study of bortezomib subcutaneous vs intravenous in relapsed multiple myeloma. In the integrated studies, the safety profile of bortezomib was similar in patients with multiple myeloma and mantle cell lymphoma.

In the integrated analysis, the most commonly reported (>20%) adverse reactions were nausea (49%), diarrhea (46%), asthenic conditions including fatigue (41%) and weakness (11%), peripheral neuropathies (38%), thrombocytopenia (32%), vomiting (28%), constipation (25%), and pyrexia (21%). Eleven percent (11%) of patients experienced at least one episode of ≥Grade 4 toxicity, most commonly thrombocytopenia (4%) and neutropenia (2%).

In the Phase 2 relapsed multiple myeloma clinical trials of bortezomib administered intravenously, local skin irritation was reported in 5% of patients, but extravasation of bortezomib was not associated with tissue damage.

Serious Adverse Reactions and Adverse Reactions Leading to Treatment Discontinuation in the Integrated Summary of Safety

A total of 26% of patients experienced a serious adverse reaction during the studies. The most commonly reported serious adverse reactions included diarrhea, vomiting and pyrexia (3% each), nausea, dehydration, and thrombocytopenia (2% each) and pneumonia, dyspnea, peripheral neuropathies, and herpes zoster (1% each).

Adverse reactions leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), and fatigue, thrombocytopenia, and diarrhea (2% each).

In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis.

Most Commonly Reported Adverse Reactions in the Integrated Summary of Safety

The most common adverse reactions are shown in Table 13. All adverse reactions occurring at ≥10% are included. In the absence of a randomized comparator arm, it is often not possible to distinguish between adverse events that are drug-caused and those that reflect the patient's underlying disease. Please see the discussion of specific adverse reactions that follows.

Table 13: Most Commonly Reported (≥ 10% Overall) Adverse Reactions in Integrated Analyses of Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma Studies Using the 1.3 mg/m2 Dose (N=1163)
All Patients
(N=1163)
Multiple Myeloma
(N=1008)
Mantle Cell Lymphoma
(N=155)
Adverse ReactionsAll≥Grade 3All≥Grade 3All≥Grade 3
*
Represents High Level Term Peripheral Neuropathies NEC

Nausea

567 (49)

36 (3)

511 (51)

32 (3)

56 (36)

4 (3)

Diarrhea NOS

530 (46)

83 (7)

470 (47)

72 (7)

60 (39)

11 (7)

Fatigue

477 (41)

86 (7)

396 (39)

71 (7)

81 (52)

15 (10)

Peripheral neuropathies*

443 (38)

129 (11)

359 (36)

110 (11)

84 (54)

19 (12)

Thrombocytopenia

369 (32)

295 (25)

344 (34)

283 (28)

25 (16)

12 (8)

Vomiting NOS

321 (28)

44 (4)

286 (28)

40 (4)

35 (23)

4 (3)

Constipation

296 (25)

17 (1)

244 (24)

14 (1)

52 (34)

3 (2)

Pyrexia

249 (21)

16 (1)

233 (23)

15 (1)

16 (10)

1 (<1)

Anorexia

227 (20)

19 (2)

205 (20)

16 (2)

22 (14)

3 (2)

Anemia NOS

209 (18)

65 (6)

190 (19)

63 (6)

19 (12)

2 (1)

Headache NOS

175 (15)

8 (<1)

160 (16)

8 (<1)

15 (10)

0

Neutropenia

172 (15)

121 (10)

164 (16)

117 (12)

8 (5)

4 (3)

Rash NOS

156 (13)

8 (<1)

120 (12)

4 (<1)

36 (23)

4 (3)

Paresthesia

147 (13)

9 (<1)

136 (13)

8 (<1)

11 (7)

1 (<1)

Dizziness (excl vertigo)

129 (11)

13 (1)

101 (10)

9 (<1)

28 (18)

4 (3)

Weakness

124 (11)

31 (3)

106 (11)

28 (3)

18 (12)

3 (2)

Description of Selected Adverse Reactions from the Integrated Phase 2 and Phase 3 Relapsed Multiple Myeloma and Phase 2 Relapsed Mantle Cell Lymphoma Studies

Gastrointestinal Toxicity

A total of 75% of patients experienced at least one gastrointestinal disorder. The most common gastrointestinal disorders included nausea, diarrhea, constipation, vomiting, and appetite decreased. Other gastrointestinal disorders included dyspepsia and dysgeusia. Grade 3 adverse reactions occurred in 14% of patients; ≥Grade 4 adverse reactions were ≤1%. Gastrointestinal adverse reactions were considered serious in 7% of patients. Four percent (4%) of patients discontinued due to a gastrointestinal adverse reaction. Nausea was reported more often in patients with multiple myeloma (51%) compared to patients with mantle cell lymphoma (36%).

Thrombocytopenia

Across the studies, bortezomib-associated thrombocytopenia was characterized by a decrease in platelet count during the dosing period (Days 1 to 11) and a return toward baseline during the ten day rest period during each treatment cycle. Overall, thrombocytopenia was reported in 32% of patients. Thrombocytopenia was Grade 3 in 22%, ≥Grade 4 in 4%, and serious in 2% of patients, and the reaction resulted in bortezomib discontinuation in 2% of patients [see Warnings and Precautions (5.7)]. Thrombocytopenia was reported more often in patients with multiple myeloma (34%) compared to patients with mantle cell lymphoma (16%). The incidence of ≥Grade 3 thrombocytopenia also was higher in patients with multiple myeloma (28%) compared to patients with mantle cell lymphoma (8%).

Peripheral Neuropathy

Overall, peripheral neuropathies occurred in 38% of patients. Peripheral neuropathy was Grade 3 for 11% of patients and ≥Grade 4 for <1% of patients. Eight percent (8%) of patients discontinued bortezomib due to peripheral neuropathy. The incidence of peripheral neuropathy was higher among patients with mantle cell lymphoma (54%) compared to patients with multiple myeloma (36%).

In the bortezomib vs dexamethasone Phase 3 relapsed multiple myeloma study, among the 62 bortezomib-treated patients who experienced ≥Grade 2 peripheral neuropathy and had dose adjustments, 48% had improved or resolved with a median of 3.8 months from first onset.

In the Phase 2 relapsed multiple myeloma studies, among the 30 patients who experienced Grade 2 peripheral neuropathy resulting in discontinuation or who experienced ≥Grade 3 peripheral neuropathy, 73% reported improvement or resolution with a median time of 47 days to improvement of one grade or more from the last dose of bortezomib.

Hypotension

The incidence of hypotension (postural, orthostatic and hypotension NOS) was 8% in patients treated with bortezomib. Hypotension was Grade 1 or 2 in the majority of patients and Grade 3 in 2% and ≥Grade 4 in <1%. Two percent (2%) of patients had hypotension reported as a serious adverse reaction, and 1% discontinued due to hypotension. The incidence of hypotension was similar in patients with multiple myeloma (8%) and those with mantle cell lymphoma (9%). In addition, <1% of patients experienced hypotension associated with a syncopal reaction.

Neutropenia

Neutrophil counts decreased during the bortezomib dosing period (Days 1 to 11) and returned toward baseline during the ten day rest period during each treatment cycle. Overall, neutropenia occurred in 15% of patients and was Grade 3 in 8% of patients and ≥Grade 4 in 2%. Neutropenia was reported as a serious adverse reaction in <1% of patients and <1% of patients discontinued due to neutropenia. The incidence of neutropenia was higher in patients with multiple myeloma (16%) compared to patients with mantle cell lymphoma (5%). The incidence of ≥Grade 3 neutropenia also was higher in patients with multiple myeloma (12%) compared to patients with mantle cell lymphoma (3%).

Asthenic Conditions (Fatigue, Malaise, Weakness, Asthenia)

Asthenic conditions were reported in 54% of patients. Fatigue was reported as Grade 3 in 7% and ≥Grade 4 in <1% of patients. Asthenia was reported as Grade 3 in 2% and ≥Grade 4 in <1% of patients. Two percent (2%) of patients discontinued treatment due to fatigue and <1% due to weakness and asthenia. Asthenic conditions were reported in 53% of patients with multiple myeloma and 59% of patients with mantle cell lymphoma.

Pyrexia

Pyrexia (>38°C) was reported as an adverse reaction for 21% of patients. The reaction was Grade 3 in 1% and ≥Grade 4 in <1%. Pyrexia was reported as a serious adverse reaction in 3% of patients and led to bortezomib discontinuation in <1% of patients. The incidence of pyrexia was higher among patients with multiple myeloma (23%) compared to patients with mantle cell lymphoma (10%). The incidence of ≥Grade 3 pyrexia was 1% in patients with multiple myeloma and <1% in patients with mantle cell lymphoma.

Herpes Virus Infection

Consider using antiviral prophylaxis in subjects being treated with Bortezomib for Injection. In the randomized studies in previously untreated and relapsed multiple myeloma, herpes zoster reactivation was more common in subjects treated with bortezomib (ranging between 6% to 11%) than in the control groups (3% to 4%). Herpes simplex was seen in 1% to 3% in subjects treated with bortezomib and 1% to 3% in the control groups. In the previously untreated multiple myeloma study, herpes zoster virus reactivation in the bortezomib, melphalan and prednisone arm was less common in subjects receiving prophylactic antiviral therapy (3%) than in subjects who did not receive prophylactic antiviral therapy (17%).

Retreatment in Relapsed Multiple Myeloma

A single-arm trial was conducted in 130 patients with relapsed multiple myeloma to determine the efficacy and safety of retreatment with intravenous bortezomib. The safety profile of patients in this trial is consistent with the known safety profile of bortezomib-treated patients with relapsed multiple myeloma as demonstrated in Tables 10, 11, and 13; no cumulative toxicities were observed upon retreatment. The most common adverse drug reaction was thrombocytopenia which occurred in 52% of the patients. The incidence of ≥Grade 3 thrombocytopenia was 24%. Peripheral neuropathy occurred in 28% of patients, with the incidence of ≥Grade 3 peripheral neuropathy reported at 6%. The incidence of serious adverse reactions was 12.3%. The most commonly reported serious adverse reactions were thrombocytopenia (3.8%), diarrhea (2.3%), and herpes zoster and pneumonia (1.5% each).

Adverse reactions leading to discontinuation occurred in 13% of patients. The reasons for discontinuation included peripheral neuropathy (5%) and diarrhea (3%).

Two deaths considered to be bortezomib-related occurred within 30 days of the last bortezomib dose; one in a patient with cerebrovascular accident and one in a patient with sepsis.

Additional Adverse Reactions from Clinical Studies

The following clinically important serious adverse reactions that are not described above have been reported in clinical trials in patients treated with bortezomib administered as monotherapy or in combination with other chemotherapeutics. These studies were conducted in patients with hematological malignancies and in solid tumors.

Blood and Lymphatic System Disorders: Anemia, disseminated intravascular coagulation, febrile neutropenia, lymphopenia, leukopenia

Cardiac Disorders: Angina pectoris, atrial fibrillation aggravated, atrial flutter, bradycardia, sinus arrest, cardiac amyloidosis, complete atrioventricular block, myocardial ischemia, myocardial infarction, pericarditis, pericardial effusion, Torsades de pointes, ventricular tachycardia

Ear and Labyrinth Disorders: Hearing impaired, vertigo

Eye Disorders: Diplopia and blurred vision, conjunctival infection, irritation

Gastrointestinal Disorders: Abdominal pain, ascites, dysphagia, fecal impaction, gastroenteritis, gastritis hemorrhagic, hematemesis, hemorrhagic duodenitis, ileus paralytic, large intestinal obstruction, paralytic intestinal obstruction, peritonitis, small intestinal obstruction, large intestinal perforation, stomatitis, melena, pancreatitis acute, oral mucosal petechiae, gastroesophageal reflux

General Disorders and Administration Site Conditions: Chills, edema, edema peripheral, injection site erythema, neuralgia, injection site pain, irritation, malaise, phlebitis

Hepatobiliary Disorders: Cholestasis, hepatic hemorrhage, hyperbilirubinemia, portal vein thrombosis, hepatitis, liver failure

Immune System Disorders: Anaphylactic reaction, drug hypersensitivity, immune complex mediated hypersensitivity, angioedema, laryngeal edema

Infections and Infestations: Aspergillosis, bacteremia, bronchitis, urinary tract infection, herpes viral infection, listeriosis, nasopharyngitis, pneumonia, respiratory tract infection, septic shock, toxoplasmosis, oral candidiasis, sinusitis, catheter-related infection

Injury, Poisoning and Procedural Complications: Catheter-related complication, skeletal fracture, subdural hematoma

Investigations: Weight decreased

Metabolism and Nutrition Disorders: Dehydration, hypocalcemia, hyperuricemia, hypokalemia, hyperkalemia, hyponatremia, hypernatremia

Musculoskeletal and Connective Tissue Disorders: Arthralgia, back pain, bone pain, myalgia, pain in extremity

Nervous System Disorders: Ataxia, coma, dizziness, dysarthria, dysesthesia, dysautonomia, encephalopathy, cranial palsy, grand mal convulsion, headache, hemorrhagic stroke, motor dysfunction, neuralgia, spinal cord compression, paralysis, postherpetic neuralgia, transient ischemic attack

Psychiatric Disorders: Agitation, anxiety, confusion, insomnia, mental status change, psychotic disorder, suicidal ideation

Renal and Urinary Disorders: Calculus renal, bilateral hydronephrosis, bladder spasm, hematuria, hemorrhagic cystitis, urinary incontinence, urinary retention, renal failure (acute and chronic), glomerular nephritis proliferative

Respiratory, Thoracic and Mediastinal Disorders: Acute respiratory distress syndrome, aspiration pneumonia, atelectasis, chronic obstructive airways disease exacerbated, cough, dysphagia, dyspnea, dyspnea exertional, epistaxis, hemoptysis, hypoxia, lung infiltration, pleural effusion, pneumonitis, respiratory distress, pulmonary hypertension

Skin and Subcutaneous Tissue Disorders: Urticaria, face edema, rash (which may be pruritic), leukocytoclastic vasculitis, pruritus

Vascular Disorders: Cerebrovascular accident, cerebral hemorrhage, deep venous thrombosis, hypertension, peripheral embolism, pulmonary embolism, pulmonary hypertension

6.2 Postmarketing Experience

The following adverse reactions have been identified from the worldwide postmarketing experience with bortezomib. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

Cardiac Disorders: Cardiac tamponade

Ear and Labyrinth Disorders: Deafness bilateral

Eye Disorders: Optic neuropathy, blindness, chalazion/blepharitis

Gastrointestinal Disorders: Ischemic colitis

Infections and Infestations: Progressive multifocal leukoencephalopathy (PML), ophthalmic herpes, herpes meningoencephalitis

Nervous System Disorders: Posterior reversible encephalopathy syndrome (PRES, formerly RPLS), Guillain-Barré syndrome, demyelinating polyneuropathy

Respiratory, Thoracic and Mediastinal Disorders: Acute diffuse infiltrative pulmonary disease

Skin and Subcutaneous Tissue Disorders: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), acute febrile neutrophilic dermatosis (Sweet's syndrome)

Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.